SCHEMBL13065747

SCHEMBL13065747

CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCOC(CC)C(=O)OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.48
CYP3A4 P08684 2/20 0.48
ALOX15 P16050 2/20 0.48
HSD17B10 Q99714 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
TSHR P16473 1/20 0.48
NR1I2 O75469 2/20 0.47
PTGS2 P35354 2/20 0.47
ADORA3 P0DMS8 2/20 0.47
PGR P06401 1/20 0.47
PDE4D Q08499 1/20 0.47
CNR1 P21554 1/20 0.46
CNR2 P34972 1/20 0.46
F7 P08709 3/20 0.45
F3 P13726 3/20 0.45
CYP19A1 P11511 3/20 0.45
MAPT P10636 2/20 0.45
OXER1 Q8TDS5 2/20 0.45
PTGS1 P23219 2/20 0.45
PPARG P37231 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15726990 1.00 ALDH1A1 (0.48) ALDH1A1CYP3A4ALOX15HSD17B10TDP1
SCHEMBL21052411 0.90 ALDH1A1 (0.49) ALDH1A1CYP3A4ALOX15HSD17B10TDP1
SCHEMBL21052413 0.90 ALDH1A1 (0.49) ALDH1A1CYP3A4ALOX15HSD17B10TDP1
SCHEMBL3688338 0.89 ALDH1A1 (0.55) ALDH1A1CYP3A4ALOX15HSD17B10TDP1
SCHEMBL3688336 0.89 ALDH1A1 (0.55) ALDH1A1CYP3A4ALOX15HSD17B10TDP1
SCHEMBL20086311 0.86 ALDH1A1 (0.47) ALDH1A1CYP3A4ALOX15HSD17B10TDP1
SCHEMBL20086306 0.86 ALDH1A1 (0.50) ALDH1A1CYP3A4ALOX15HSD17B10TDP1
SCHEMBL20086304 0.86 ALDH1A1 (0.46) ALDH1A1CYP3A4ALOX15HSD17B10TDP1
SCHEMBL23520453 0.85 ALDH1A1 (0.44) ALDH1A1CYP3A4ALOX15HSD17B10TDP1
Icosabutate SCHEMBL21585131 0.85 ALDH1A1 (0.51) ALDH1A1CYP3A4ALOX15HSD17B10TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735436-B2 Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas PRONOVA BIOPHARMA NORGE AS (NO) 2014-05-27 US claimed
US-12599580-B2 Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same BASF AS (NO) 2026-04-14 US disclosed
US-20240325336-A1 COMBINATION THERAPIES COMPRISING OXYGEN-CONTAINING STRUCTURALLY ENHANCED FATTY ACIDS FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS NORTHSEA THERAPEUTICS B.V. (NL) 2024-10-03 US disclosed
US-20230090432-A1 COMPOSITION COMPRISING A LIPID COMPOUND, A TRIGLYCERIDE, AND A SURFACTANT, AND METHODS OF USING THE SAME PRONOVA BIOPHARMA NORGE AS (NO) 2023-03-23 US disclosed
US-11351139-B2 Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same BASF AS (NO) 2022-06-07 US disclosed
US-20210177794-A1 FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS BASF AS (NO) 2021-06-17 US disclosed
CN-105120842-B Compositions comprising lipid compounds, triglycerides and surfactants and methods of using the same 普罗诺瓦生物医药挪威公司 2020-12-01 CN disclosed
EP-3720431-A1 FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS BASF AS (NO) 2020-10-14 EP disclosed
CN-111712240-A Fatty acid derivatives for the treatment of non-alcoholic steatohepatitis 巴斯夫股份公司 2020-09-25 CN disclosed
EP-3578170-A1 A COMPOSITION COMPRISING A LIPID COMPOUND, A TRIGLYCERIDE, AND A SURFACTANT, AND METHODS OF USING THE SAME BASF AS (NO) 2019-12-11 EP disclosed
EP-2961384-B1 A COMPOSITION COMPRISING A LIPID COMPOUND, A TRIGLYCERIDE, AND A SURFACTANT, AND METHODS OF USING THE SAME BASF AS (NO) 2019-08-28 EP disclosed
EP-2961384-B1 A COMPOSITION COMPRISING A LIPID COMPOUND, A TRIGLYCERIDE, AND A SURFACTANT, AND METHODS OF USING THE SAME BASF AS (NO) 2019-08-28 EP disclosed
WO-2019111048-A1 FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS BASF AS (NO) 2019-06-13 WO disclosed
US-20180110747-A1 USE OF THIA OXO COMPOUNDS FOR LOWERING APO C3 BASF AS (NO) 2018-04-26 US disclosed
US-20180110747-A1 USE OF THIA OXO COMPOUNDS FOR LOWERING APO C3 BASF AS (NO) 2018-04-26 US disclosed
US-20160206585-A1 A COMPOSITION COMPRISING A LIPID COMPOUND, A TRIGLYCERIDE, AND A SURFACTANT, AND METHODS OF USING THE SAME BASF AS (NO) 2016-07-21 US disclosed
US-8735436-B2 Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas PRONOVA BIOPHARMA NORGE AS (NO) 2014-05-27 US disclosed
US-8735436-B2 Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas PRONOVA BIOPHARMA NORGE AS (NO) 2014-05-27 US disclosed
WO-2010128401-A1 POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS PRONOVA BIOPHARMA NORGE AS (NO) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210177794-A1 FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS CPT1A, NR1H3, NR1H2 ALDH1A1 162/4885CYP3A4 796/4885ALOX15 65/4885
US-11351139-B2 Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same LIPA, SCD5, SBDS ALDH1A1 1748/4885CYP3A4 864/4885ALOX15 10/4885
US-20240325336-A1 COMBINATION THERAPIES COMPRISING OXYGEN-CONTAINING STRUCTURALLY ENHANCED FATTY ACIDS FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS ACACA, PC, ACACB ALDH1A1 525/4885CYP3A4 1003/4885ALOX15 176/4885
US-12599580-B2 Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same LIPA, LIPC, LIPG ALDH1A1 3488/4885CYP3A4 2293/4885ALOX15 32/4885
US-20230090432-A1 COMPOSITION COMPRISING A LIPID COMPOUND, A TRIGLYCERIDE, AND A SURFACTANT, AND METHODS OF USING THE SAME LIPA, SCD5, SBDS ALDH1A1 1748/4885CYP3A4 864/4885ALOX15 10/4885
US-20180110747-A1 USE OF THIA OXO COMPOUNDS FOR LOWERING APO C3 APOB, TTPA, APOL1 ALDH1A1 2466/4885CYP3A4 735/4885ALOX15 80/4885
US-20160206585-A1 A COMPOSITION COMPRISING A LIPID COMPOUND, A TRIGLYCERIDE, AND A SURFACTANT, AND METHODS OF USING THE SAME SCD5, LIPA, SBDS ALDH1A1 1492/4885CYP3A4 653/4885ALOX15 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.